# Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

> **NCT06441214** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 212 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia (WM)

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06441214
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441214, "Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06441214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*